Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Tumor Biology

Volumn 37, Issue 9, 2016, Pages 11927-11936

  Chen, Xu ^a   Xu, Yanmei ^b   Liao, Xingyun ^a   Liao, Rongxia ^a   Zhang, Luping ^a   Niu, Kai ^a   Li, Tao ^a   Li, Dezhi ^a   Chen, Zhengtang ^a   Duan, Yuzhong ^a   Sun, Jianguo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b People's Hospital of Leshan   (China)

Author keywords

Bioinformatics; Biomarker; miRNAs; NSCLC; Plasma; Radiosensitivity

Indexed keywords

MICRORNA; MICRORNA 1 3P; MICRORNA 1297; MICRORNA 153 3P; MICRORNA 193A 3P; MICRORNA 206; MICRORNA 302 E; MICRORNA 328 3P; MICRORNA 372 3P; MICRORNA 495 3P; MICRORNA 520A 3P; MICRORNA 520B; MICRORNA 520D 3P; MICRORNA 520E; MICRORNA 613; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL LINE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; H460 CANCER CELL LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RADIOSENSITIVITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; PROGNOSIS; RADIATION TOLERANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE;

EID: 84963699434     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5052-8     Document Type: Article

References (37)

1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
2. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5 Suppl 4:S389–96.
3. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52(2):155–63.
4. Dessard-Diana B, Manoux D, Diana C, Housset M, Baillet F. Discussion on the role of radiotherapy in non-small cell lung cancer apropos of 137 non-metastatic cases. Cancer Radiother. 1997;1(2):154–8.
5. Lindblom E, Dasu A, Toma-Dasu I. Optimal fractionation in radiotherapy for non-small cell lung cancer—a modelling approach. Acta Oncol. 2015;54(9):1592–8.
6. Gordon JJ, Snyder K, Zhong H, Barton K, Sun Z, Chetty IJ, et al. Extracting the normal lung dose-response curve from clinical DVH data: a possible role for low dose hyper-radiosensitivity, increased radioresistance. Phys Med Biol. 2015;60(17):6719–32.
7. Ma D, Jia H, Qin M, Dai W, Wang T, Liang E, et al. MiR-122 induces radiosensitization in non-small cell lung cancer cell line. Int J Mol Sci. 2015;16(9):22137–50.
8. Nikolaishvilli-Feinberg N, Cohen SM, Midkiff B, Zhou Y, Olorvida M, Ibrahim JG, et al. Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. J Histochem Cytochem. 2014;62(3):185–96.
9. Xu T, Liao Z, O’Reilly MS, Levy LB, Welsh JW, Wang LE, et al. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014;113(3):379–84.
10. Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys. 2010;76(1):5–8.
11. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012;107(8):1361–73.
12. Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, et al. Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One. 2010;5(7), e11397.
13. Wang W, Zhang E, Lin C. MicroRNAs in tumor angiogenesis. Life Sci. 2015;136:28–35.
14. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848–56.
15. Zhang X, Hu S, Zhang X, Wang L, Zhang X, Yan B, et al. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2014;443(3):1078–84.
16. Xu K, Chen Z, Qin C, Song X. miR-7 inhibits colorectal cancer cell proliferation and induces apoptosis by targeting XRCC2. Onco Targets Ther. 2014;7:325–32.
17. Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, et al. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Res. 2015;43(8):4075–86.
18. Feng ZM, Qiu J, Chen XW, Liao RX, Liao XY, Zhang LP, et al. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium. BMC Cancer. 2015;15(1):645.
19. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
21. Socha J, Kołodziejczyk M, Kępka L. Outcome after PET-CT based radiotherapy for non-small cell lung cancer. Pneumonol Alergol Pol. 2013;81(1):30–9.
22. Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9(1):91.
23. Jereczek-Fossa BA, Bossi-Zanetti I, Mauro R, Beltramo G, Fariselli L, Bianchi LC, et al. CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer: a prospective evaluation of 95 patients/118 lesions. Strahlenther Onkol. 2013;189(6):448–55.
24. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136(4):586–91.
25. Skrzypski M, Czapiewski P, Goryca K, Jassem E, Wyrwicz L, Pawłowski R, et al. Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer. 2014;110(4):991–1000.
26. Yang J, Liu H, Wang H, Sun Y. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer. Pathol Res Pract. 2013;209(8):490–4.
27. Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 2014;9(2), e87780.
28. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67(23):11111–6.
29. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494–503.
30. Liu YJ, Lin YF, Chen YF, Luo EC, Sher YP, Tsai MH, et al. MicroRNA-449a enhances radiosensitivity in CL1-0 lung adenocarcinoma cells. PLoS One. 2013;8(4), e62383.
31. Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P, et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol. 2014;35(7):6557–65.
32. He Z, Liu Y, Xiao B, Qian X. miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. Biochem Biophys Res Commun. 2015;457(3):235–41.
33. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28(10):1721–6.
34. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91(4):579–87.
35. Halimi M, Parsian H, Asghari SM, Sariri R, Moslemi D, Yeganeh F, et al. Clinical translation of human microRNA 21 as a potential biomarker for exposure to ionizing radiation. Transl Res. 2014;163(6):578–84.
36. Liang Z, Ahn J, Guo D, Votaw JR, Shim H. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2013;30(4):1008–16.
37. Song L, Li Y, Li W, Wu S, Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem. 2014;115(7):1234–42.